In early-stage ER‑positive, HER2‑negative breast cancer with germline BRCA1 mutation and high genomic risk, how should the choice between neoadjuvant and adjuvant chemotherapy be approached?

I typically do not use the BRCA1 mutation as the determining factor for a neo-adjuvant or adjuvant chemotherapy approach in patients with hormone receptor-positive, HER2-negative non-metastatic breast cancer. However, if the patient's characteristics and their disease would fit the eligibility crite...